J&J Maps Robotics Growth Arc In 2028 As Ottava, Monarch Near Key Regulatory Milestones
Johnson & Johnson expects a planned orthopedics separation to unfold over time, with a potential spin-off in the second half of 2027, drawing on experience from its earlier consumer health carve-out to guide execution.
Medtech Insight - January 14, 2026

Medtech 2026: Collaboration, Coverage Improvements Top Industry Wish Lists
Wishes for 2026 from our medtech experts focused on value-based care, faster reimbursements, and better collaboration. Key ideas included enhancing patient engagement, reducing waste, and aligning coverage policies to improve health outcomes and innovation.
Medtech Insight - January 14, 2026

Medtech 2026: AI Shows Patient Care Potential, But Regulation Remains Tricky
AI in medtech offers exciting potential for improving patient care and operational efficiency, but faces significant regulatory challenges. Ensuring data quality and building trust among users are essential for successful AI integration in healthcare, our expert panel said.
Medtech Insight - January 14, 2026

People On The Move: Appointments at Haleon, DSM-Firmenich, SkinBioTherapeutics
A round-up of the latest health & wellness people moves: Haleon adds chief growth officer role; DSM-Firmenich names HR chief; SkinBioTherapeutics makes additions to its board.
HBW Insight - January 14, 2026

With Two Partnered Launches Expected In 2026, Protagonist Looks To Next Chapter
Upcoming product launches from partnerships with J&J and Takeda could generate billions in royalties for the biotech, which now aims to build an in-house portfolio of next-generation oral obesity drugs and I&I therapies.
Scrip - January 14, 2026

Allos Raises $5m For AI-Driven Complex Generic Reformulation Platform
Oxford-based Allos is scaling up its AI platform, which aims to revive investments into reformulating complex generics.
Generics Bulletin - January 14, 2026

J.P. Morgan: Teva Targets Long-Term Value Over Fast Uptake For Long-Acting Olanzapine
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Generics Bulletin - January 14, 2026

Amphastar Expands Peptide Push With Synthetic Corticotropin Licensing Agreement
Amphastar is looking to a “strategically important addition to our growing proprietary peptide portfolio,” after striking an exclusive licensing agreement with China-based Nanjing Hanxin Pharmaceutical Technology.
Generics Bulletin - January 14, 2026

Building Companies Like Experiments: The Flagship Pioneering Model
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
In Vivo - January 14, 2026

The Challenge Of Measuring Almost Nothing: HER2 Testing Enters Ultralow Era
Enhertu's approval for ever-lower levels of HER2 expression is pushing standard immunohistochemistry assays beyond their limits. Pathologists say they have a solution.
In Vivo - January 14, 2026

J.P. Morgan: BridgeBio Shares Hit All-Time High After Attruby Sales, Pipeline Updates
The Palo Alto,CA-based biotech's promising sales update for Attruby sets up a potentially intense market share battle in the transthyretin amyloid cardiomyopathy space.
Scrip - January 14, 2026

Sino Biopharm Buys siRNA-Focused Hygieia In Cardiovascular Drive
The $172m acquisition will bring in Kylo-11, a Lp(a) inhibitor with potential once-yearly dosing, as well as other ultra long-acting siRNA candidates directed at APOC3, PCSK9 and other undisclosed targets in cardiovascular diseases.
Scrip - January 14, 2026

US FDA Warns Private Labeler For Quality Violations
Private Label Skin Care Inc. has violated Current Good Manufacturing Practice regulations for pharmaceuticals, according to the agency.
HBW Insight - January 14, 2026

J.P. Morgan Notebook: Strategies For Business Development, FDA Change & Pricing
Execs from Merck and Italfarmaco talk business development, while Takeda's Plump addresses regulatory uncertainty in the US and Ionis CEO Monia discusses pricing for Tryngolza, plus more news from day two of J.P. Morgan.
Scrip - January 14, 2026

US OTC Drug Industry’s Input On PDUFA Reauthorization Emphasizes Switch NDA Output
In PDUFA reauthorization subgroup meetings, CHPA suggests expanding FDA’s special protocol assessment program to include OTC drug studies before FDA notes Congress has required it to provide switch-specific guidance before current PDUFA expires.
HBW Insight - January 14, 2026